EF Cutoff for Risk in Non-Cardiac Surgery
An ejection fraction below 30% defines markedly increased perioperative risk in non-cardiac surgery, with mortality risk more than doubling compared to patients without heart failure 1.
Risk Stratification by EF Thresholds
The 2026 AHA/ACC guideline provides the most definitive contemporary data on EF-based risk stratification 1:
- LVEF <30%: Adjusted odds ratio of 2.35 for 90-day mortality (crude mortality 8.34%)
- LVEF 30-39%: Adjusted odds ratio of 1.85 for 90-day mortality (crude mortality 6.58%)
- LVEF 40-49%: Adjusted odds ratio of 1.53 for 90-day mortality (crude mortality 5.11%)
- LVEF ≥50%: Adjusted odds ratio of 1.51 for 90-day mortality (crude mortality 4.88%)
This data from 609,735 patients undergoing non-cardiac surgery demonstrates a clear stepwise increase in mortality as EF declines, with the most dramatic risk elevation occurring below 30%.
Practical Clinical Thresholds
The 30% threshold represents the critical cutoff where perioperative risk becomes substantially elevated. Older data from carotid surgery identified 35% as a threshold where perioperative cardiac complications occurred in 43% of cases versus 9% in those with higher EF 2. However, the more recent and larger guideline dataset supports 30% as the contemporary standard 1.
A 2021 study identified 58% as an optimal cutoff for predicting perioperative adverse cardiovascular events (sensitivity 80%, specificity 61%) 3, but this represents a statistical optimization rather than a clinically actionable threshold for high-risk designation.
Critical Context: EF Alone Is Insufficient
The presence of active heart failure symptoms matters more than the EF number itself. Patients with compensated heart failure and low EF may have lower risk than those with HFpEF and clinical decompensation 1. The guideline emphasizes that patients with active HF symptoms or signs are at higher risk than those with compensated HF or history of HF alone 1.
For patients with advanced heart failure (NYHA class III-IV) who are clinically decompensated or hemodynamically unstable, postpone elective surgery regardless of the specific EF value and obtain cardiology consultation 1.
Perioperative Management Based on EF
Continue guideline-directed medical therapy (GDMT) through the perioperative period for all patients with heart failure, with one critical exception 1:
- Withhold SGLT2 inhibitors for 3-4 days before surgery (canagliflozin, dapagliflozin, empagliflozin ≥3 days; ertugliflozin ≥4 days) to prevent perioperative metabolic acidosis 1
- Continue all other HF medications (ACE inhibitors, ARBs, beta-blockers, mineralocorticoid receptor antagonists) unless specifically contraindicated 1
Interruption of GDMT without specific indication increases mortality 1.
Common Pitfalls
- Do not use EF as the sole risk determinant. Functional capacity, volume status, and clinical stability are more robust predictors of short-term perioperative risk 4
- Do not assume preserved EF equals low risk. HFpEF with congestion or right ventricular dysfunction may carry higher risk than compensated HFrEF 4
- Do not forget to assess for diastolic dysfunction, venous congestion, and right ventricular function beyond the EF number 4